Explore this page to view content from our Annual Meeting Impact Report or download the full report at the link below.
A letter from Manish Raisinghani, Target ALS CEO
The 2026 Target ALS Annual Meeting was a powerful reminder of what is possible when urgency, collaboration, and innovation come together in pursuit of a shared goal: a world where everyone with ALS can live a long, quality life.
A letter from Dan Doctoroff, Target ALS Founder & Chairman
For a long time, ALS was something that haunted my family. My father died from ALS in 2002. Years later, my uncle was diagnosed with the disease and passed away as well. Through both experiences, I came to understand not only the devastation of ALS but also the widespread belief that it was impossible to solve.
I have never accepted that.
Every year, the Target ALS Annual Meeting brings together the scientists, clinicians, and partners working to change what an ALS diagnosis means. This year, the room was electric with new clinical data, breakthrough biology, and a clearer picture than ever of how we get to treatments that work. Here’s what happened, and what comes next.
From early-stage bets to clinical trial data, see how we’re moving treatments closer to the people who need them.
The tools to diagnose, track, and treat ALS are being built. It starts with biomarkers.
Before we can treat ALS, we have to understand it.
The most powerful new tool in the lab.
The infrastructure behind the breakthroughs.
The work, in detail.
When we see gaps, we fill them with experts.
Experts sit down and explore two frontiers in ALS science: biomarkers and the future of AI/ML in research.
One mutation. Dozens of relatives. Different outcomes.
Join the Target ALS community today to receive updates on the impact of our work and opportunities to advance our mission.
